Changes in hepatic phase I and phase II biotransformation enzyme expression and glutathione levels following atrazine exposure in female rats / Arthur D. Zimmerman, Charles B. Breckenridge, Kun D. Yi, Pragati Sawhney Coder, Desiree Wanders, Robert L. Judd, Chad D. Foradori
Abstract 1.To determine the effects of repeated atrazine (ATR) treatment on hepatic phase I and II enzymes, adult female rats were treated with vehicle or 100 mg/kg of ATR for 1, 2, 3 or 4 days. Glutathione- s -transferases (GST) mRNA expression, protein levels (mu, pi, alpha, omega), and activity (cytosolic and microsomal), along with bioavailable glutathione (GSH) were assayed. 2.GST expression, concentrations and activity were increased, along with GSH levels, in animals treated with ATR for 3 and 4 days. 3.A subsequent study was performed with animals treated with vehicle, 6.5, 50 or 100 mg/kg/day for 4, 8 or 14 days. Expression of hepatic phase I CYP 450 enzymes was evaluated in conjugation with GST expression, protein and activity. Nineteen of the 45 CYP enzymes assayed displayed increased mRNA levels after eight days of treatment in animals treated with 50 or 100 mg/kg/day. After 14 days of treatment, all CYP expression levels returned to control levels except for CYP2B2, CYP2B3, CYP2C7, CYP2C23, CYP2E1, CYP3A9, CYP4A3 and CYP27A1, which remained elevated. 4.Results indicate that there may be a habituation or adaptation of liver phase I and phase II expression following repeated ATR treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Xenobiotica - 48(2018), 9, Seite 867-881 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zimmerman, Arthur D. [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Umfang: |
1 Online-Ressource (15 p) |
|---|
| doi: |
10.1080/00498254.2017.1374486 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011110309 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011110309 | ||
| 003 | DE-627 | ||
| 005 | 20230713210733.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/00498254.2017.1374486 |2 doi | |
| 035 | |a (DE-627)KFL011110309 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/00498254.2017.1374486 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Zimmerman, Arthur D. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Changes in hepatic phase I and phase II biotransformation enzyme expression and glutathione levels following atrazine exposure in female rats |c Arthur D. Zimmerman, Charles B. Breckenridge, Kun D. Yi, Pragati Sawhney Coder, Desiree Wanders, Robert L. Judd, Chad D. Foradori |
| 264 | 1 | |c 2018 | |
| 300 | |a 1 Online-Ressource (15 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract 1.To determine the effects of repeated atrazine (ATR) treatment on hepatic phase I and II enzymes, adult female rats were treated with vehicle or 100 mg/kg of ATR for 1, 2, 3 or 4 days. Glutathione- s -transferases (GST) mRNA expression, protein levels (mu, pi, alpha, omega), and activity (cytosolic and microsomal), along with bioavailable glutathione (GSH) were assayed. 2.GST expression, concentrations and activity were increased, along with GSH levels, in animals treated with ATR for 3 and 4 days. 3.A subsequent study was performed with animals treated with vehicle, 6.5, 50 or 100 mg/kg/day for 4, 8 or 14 days. Expression of hepatic phase I CYP 450 enzymes was evaluated in conjugation with GST expression, protein and activity. Nineteen of the 45 CYP enzymes assayed displayed increased mRNA levels after eight days of treatment in animals treated with 50 or 100 mg/kg/day. After 14 days of treatment, all CYP expression levels returned to control levels except for CYP2B2, CYP2B3, CYP2C7, CYP2C23, CYP2E1, CYP3A9, CYP4A3 and CYP27A1, which remained elevated. 4.Results indicate that there may be a habituation or adaptation of liver phase I and phase II expression following repeated ATR treatment | ||
| 653 | |a Female | ||
| 653 | |a habituation | ||
| 653 | |a herbicides | ||
| 653 | |a liver enzymes | ||
| 653 | |a rat | ||
| 700 | 1 | |a Breckenridge, Charles B. |e verfasserin |4 aut | |
| 700 | 1 | |a Yi, Kun D. |e verfasserin |4 aut | |
| 700 | 1 | |a Sawhney Coder, Pragati |e verfasserin |4 aut | |
| 700 | 1 | |a Wanders, Desiree |e verfasserin |4 aut | |
| 700 | 1 | |a Judd, Robert L. |e verfasserin |4 aut | |
| 700 | 1 | |a Foradori, Chad D. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Xenobiotica |d Abingdon : Taylor & Francis Group, 1971 |g 48(2018), 9, Seite 867-881 |h Online-Ressource |w (DE-627)KFL000005959 |w (DE-600)1485113-1 |w (DE-576)079719163 |x 1366-5928 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2018 |g number:9 |g pages:867-881 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/00498254.2017.1374486 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_01 | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2018 |e 9 |h 867-881 | ||